The Food and Drug Administration Jan. 25 approved three new related pharmaceutical products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
The products are Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets. All three are manufactured by Osaka, Japan-based Takeda Pharmaceutical Co.
Alogliptin is a new active ingredient, while metformin hydrochloride and pioglitazone already are FDA-approved for management of type 2 diabetes, the agency said. Pioglitazone is the active ingredient in the Takeda drug Actos, which now has generic competition (10 PLIR 1412, 11/2/12
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.